ClinVar Miner

Submissions for variant NM_004168.4(SDHA):c.1A>G (p.Met1Val)

gnomAD frequency: 0.00013  dbSNP: rs1061517
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000230468 SCV000288128 pathogenic Mitochondrial complex II deficiency, nuclear type 1; Paragangliomas 5 2024-01-28 criteria provided, single submitter clinical testing This sequence change affects the initiator methionine of the SDHA mRNA. The next in-frame methionine is located at codon 114. This variant is present in population databases (rs1061517, gnomAD 0.02%). Disruption of the initiator codon has been observed in individuals with autosomal dominant gastrointestinal stromal tumor syndrome, autosomal dominant paraganglioma-pheochromocytoma syndrome (PMID: 26722403, 28384794, 29625052, 30068732), and/or autosomal recessive mitochondrial complex II deficiency (PMID: 10746566, 26334176). ClinVar contains an entry for this variant (Variation ID: 239661). This variant disrupts the N-terminal part of the SDHA protein, which is important for FAD binding (PMID: 25488574, 15989954, 21858060). While functional studies have not been performed to directly test the effect of this variant on SDHA protein function, this suggests that disruption of this region of the protein is causative of disease. For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV000567727 SCV000674973 pathogenic Hereditary cancer-predisposing syndrome 2022-08-24 criteria provided, single submitter clinical testing The p.M1? pathogenic mutation (also known as c.1A>G), located in coding exon 1 of the SDHA gene, results from an A to G substitution at nucleotide position 1. This alters the methionine residue at the initiation codon (ATG). There is an in-frame methionine 114 amino acids downstream from this initiation site which may result in an N-terminal truncation; however, direct evidence is unavailable. This alteration has been reported in at least one individual with Leigh syndrome (Baskovich B et al. Genet. Med. 2016 05;18:522-8). A different variant altering the methionine residue (c.1A>C) has been observed in an individual with Leigh syndrome who also carried a functionally deleterious SDHA alteration in trans, as well as in individuals with paraganglioma and gastrointestinal stromal tumor (GIST) (Parfait B et al. Hum. Genet. 2000 Feb;106:236-43; Bausch B et al. JAMA Oncol. 2017 Sep;3(9):1204-1212; Carrera S et al. Hered. Cancer Clin. Pract. 2019 Aug;17:23). In addition to the clinical data presented in the literature, sequence variations that modify the initiation codon are expected to result in either loss of translation initiation, N-terminal truncation, or cause a shift in the mRNA reading frame. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
GeneDx RCV000579224 SCV000680795 pathogenic not provided 2022-01-04 criteria provided, single submitter clinical testing Initiation codon variant in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 26334176, 30877234, 31665838, 29625052, 32971818, 32676327, 30068732, 33077847, Davidoff2021[Case Report])
Department of Pediatrics, Memorial Sloan Kettering Cancer Center RCV000656497 SCV000778380 pathogenic Paragangliomas 5 2018-06-06 criteria provided, single submitter clinical testing This mutation was detected in a patient with bladder cancer in our cohort. While this genomic alteration meets ACMG criteria as pathogenic, additional features suggest this variant was driving the bladder cancer in the patient it was detected are lacking. A second hit was not observed in SDHA in the tumor and SDHA/B staining were retained in the tumor sample.
Illumina Laboratory Services, Illumina RCV000656497 SCV001786669 likely pathogenic Paragangliomas 5 2022-06-15 criteria provided, single submitter clinical testing The SDHA c.1A>G (p.Met1?) variant alters the initiator methionine amino acid and the resultant protein is described as p.Met1? to denote that whether the loss of the methionine at codon 1 prevents all protein translation or causes abnormal protein formation from an alternate methionine is unknown. This variant has been reported in a heterozygous state in an individual with pheochromocytoma (Davidoff et al. 2021) as well as individuals with bladder cancer (Dubart Gault et al. 2018; Carlo et al. 2020) and melanoma (Huang et al. 2018; Aoude et al. 2020). It has also been identified as a somatic variant in a tumor sample from an individual with a carotid paraganglioma (Snezhkina et al. 2020). In addition, the c.1A>G variant was identified in at least two individuals with an autosomal recessive mitochondrial disorder (Baskovich et al. 2016; Han et al. 2019; Yang et al. 2022). Different nucleotide changes that also disrupt the initiation codon, c.1A>C, c.1A>T, c.2T>C, c.2T>G, and c.3G>C, have been reported in individuals with adrenal paraganglioma, carotid paraganglioma, gastrointestinal stromal tumors, or autosomal recessive Leigh syndrome (Parfait et al. 2000; Jiang et al. 2015; Bausch et al. 2017; Carrera et al. 2019). The c.1A>G variant is reported in the Genome Aggregation Database in three alleles at a frequency of 0.000044 in the European (non-Finnish) population (version 3.1.2). Mutagenesis studies using breast cancer cell lines expressing c.1A>G variant and wild-type cDNA showed decreased protein levels and increased accumulation of metabolites in the presence of the variant. The succinate to fumarate ratio was not significantly different from wild-type in the cell lines expressing the variant (Dubart Gault et al. 2018), but a sample from the resected pheochromocytoma from the individual with a germline c.1A>G variant did show an increased succinate to fumarate ratio as well as absent immunohistochemical staining for succinate dehydrogenase subunits A and B (Davidoff et al. 2021). Based on the available evidence, the c.1A>G (p.Met1?) variant is classified as likely pathogenic for hereditary paraganglioma-pheochromocytoma syndrome.
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden RCV000579224 SCV002009959 likely pathogenic not provided 2021-11-03 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV000656497 SCV004933589 pathogenic Paragangliomas 5 2024-02-06 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant is located within the gene translation start codon (p.Met1?) and is predicted to result in abnormal protein translation. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 35014173, 28384794, 10746566, 26722403, 32971818].

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.